SEF 19

Drug Profile

SEF 19

Latest Information Update: 20 Jul 2001

Price : $50

At a glance

  • Originator Zenyaku Kogyo
  • Class Antineoplastics
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 20 Jul 2001 No-Development-Reported for Breast cancer in Japan (Unknown route)
  • 18 Jun 1998 A preclinical study has been added to the pharmacodynamics section
  • 16 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top